This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Bristol-Myers Squibb Company (NYSE:BMY) and
AstraZeneca (LSE:AZN) announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. As previously disclosed, the payment is being made in connection with the expansion of the diabetes alliance between AstraZeneca and Bristol-Myers Squibb to incorporate the development and marketing of Amylin’s portfolio of diabetes products, and profits and losses arising from the collaboration will be shared equally.
AstraZeneca has also informed Bristol-Myers Squibb of its intention to exercise its option to acquire certain additional governance rights over key strategic and financial decisions regarding Amylin’s portfolio. The right to exercise this option will become effective once applicable anti-trust and competition approvals are received by AstraZeneca. Upon the exercise of the option an additional payment of $135 million will be made to Bristol-Myers Squibb.
“The completion of our acquisition of Amylin and the expansion of our diabetes alliance with AstraZeneca will increase and strengthen our innovative portfolio of diabetes medicines, extending its reach across the spectrum of treatment options,” said
Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb. “We are pleased to have the opportunity to work together to build on the innovative portfolio, state-of-the art manufacturing facilities and dedicated customer focus that the talented people at Amylin have created.”
Simon Lowth, interim chief executive officer, AstraZeneca, said: “We are delighted to have successfully completed the expansion of our diabetes alliance with Bristol-Myers Squibb through the addition of Amylin’s GLP-1 franchise, creating a broader disease management platform for patients, physicians and payers. We are looking forward to working with the team at Amylin to build on their success and maximize AstraZeneca’s and Bristol-Myers Squibb’s combined capabilities to make these innovative treatments available to many more diabetes patients across the world.”